The answer to that is yes and no. It is intended that some trials will be run using a biomarker to recruit and others only looking at the correlation between FTO and a response as a secondary endpoint at the end of the trial.
The upcoming EMD AML Stratum 2 trial will not be recruiting on the basis of a biomarker other than being EMD AML positive.
The answer to that is yes and no. It is intended that some...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |